Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 50%Low 2 · 33.3%Moderate 1 · 16.7%High 0 · 0%

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of AmBd + 5FC probably leads to lower mortality: 10 weeks compared with two weeks of AmBd (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.66 [0.46, 0.95]
2 studies · 231 participants
Moderate

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of AmBd + 5FC showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + FLU (low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.9 [0.69, 1.19]
4 studies · 538 participants
Low

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of AmBd + 5FC + FLU changes mortality: 10 weeks compared with two weeks of AmBd + 5FC (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 2.81 [0.33, 24.16]
1 study · 31 participants
Very low

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of AmBd + 5FC + FLU changes mortality: 10 weeks compared with two weeks of AmBd + FLU (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.43 [0.13, 1.37]
1 study · 32 participants
Very low

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of AmBd + 5FC + FLU changes mortality: 10 weeks compared with two weeks of AmBd (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1 [0.24, 4.23]
1 study · 32 participants
Very low

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of AmBd + 5FC + IFNg showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + 5FC (low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.92 [0.48, 1.77]
1 study · 88 participants
Low